[Course and treatment of progressive subacute encephalopathy caused by human immunodeficiency virus in children. The value of Botulinum toxin].
D015526:AIDS Dementia Complex / Q000150:complications* / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy / Q000209:etiology*; D018450:Disease Progression; D004341:Drug Evaluation; D005260:Female; D020233:Gait Disorders, Neurologic / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D015658:HIV Infections / Q000635:transmission; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology*; D009989:Orthotic Devices; D026741:Physical Therapy Modalities; D011782:Quadriplegia / Q000188:drug therapy / Q000209:etiology*
D019380:Anti-HIV Agents; D019274:Botulinum Toxins, Type A
Evolución y tratamiento de la encefalopatía subaguda progresiva por virus de inmunodeficiencia humana en el niño. Utilidad de la toxina botulínica.